Method for treatment of air way obstructions
A method for reducing a volume of a tongue includes providing an ablation apparatus with an energy delivery device configured to be coupled to an energy source. The energy delivery device is positioned in an interior of the tongue. A sufficient amount of energy is delivered from the energy delivery device in the interior of the tongue to ablate a section of the tongue without damaging the main branches of the hypoglossal nerve. The energy delivery device is thereafter removed from the interior of the tongue.
Latest Somnus Medical Technologies, Inc. Patents:
1. Field of the Invention
This invention relates to a method for creating cell necrosis regions, and more particularly to a method that creates cell necrosis regions in a tongue by introducing one or more energy delivery devices through an undersurface of the tongue and into its interior.
2. Description of Related Art
Sleep-apnea syndrome is a medical condition characterized by daytime hypersomnolence, morning arm aches, intellectual deterioration, cardiac arrhythmias, snoring and thrashing during sleep. It is caused by frequent episodes of apnea during the patient's sleep. The syndrome is classically subdivided into two types. One type, termed "central sleep apnea syndrome", is characterized by repeated loss of respiratory effort. The second type, termed obstructive sleep apnea syndrome, is characterized by repeated apneic episodes during sleep resulting from obstruction of the patient's upper airway or that portion of the patient's respiratory tract which is cephalad to, and does not include, the larynx.
Treatment thus far includes various medical, surgical and physical measures. Medical measures include the use of medications such as protriptyline, medroxyprogesterone, acetazolamide, theophylline, nicotine and other medications in addition to avoidance of central nervous system depressants such as sedatives or alcohol. The medical measures above are sometimes helpful but are rarely completely effective. Further, the medications frequently have undesirable side effects.
Surgical interventions have included uvulopalatopharyngoplasty, tonsillectomy, surgery to correct severe retrognathia and tracheostomy. These procedures may be effective but the risk of surgery in these patients can be prohibitive and the procedures are often unacceptable to the patients.
Physical measures have included weight loss, nasopharygeal airways, nasal CPAP and various tongue retaining devices used nocturnally. These measures may be partially effective but are cumbersome, uncomfortable and patients often will not continue to use these for prolonged periods of time. Weight loss may be effective but is rarely achieved by these patients.
In patients with central sleep apnea syndrome, phrenic nerve or diaphragmatic pacing has been used. Phrenic nerve or diaphragmatic pacing includes the use of electrical stimulation to regulate and control the patient's diaphragm which is innervated bilaterally by the phrenic nerves to assist or support ventilation. This pacing is disclosed in Direct Diaphragm Stimulation by J. Mugica et al. PACE vol. Jan. 10-Feb. 1998, Part II, Preliminary Test of a Muscular Diaphragm Pacing System on Human Patients by J. Mugica et al. from Neurostimulation: An Overview 1985 pp. 263-279 and Electrical Activation of Respiration by Nochomovitez IEEE Eng. in Medicine and Biology; June, 1993.
However, it was found that many of these patients also have some degree of obstructive sleep apnea which worsens when the inspiratory force is augmented by the pacer. The ventilation induced by the activation of the diaphragm also collapses the upper airway upon inspiration and draws the patient's tongue anteriorly down the throat chocking the patient. These patients then require tracheostomies for adequate treatment.
A physiological laryngeal pacemaker as described in Physiological Laryngeal Pacemaker by F. Kaneko et al. from Trans Am Soc Artif Intern Organs 1985 senses volume displaced by the lungs and stimulates the appropriate nerve to open the patient's glottis to treat dyspnea. This apparatus is not effective for treatment of sleep apnea. The apparatus produces a signal proportional in the displaced air volume of the lungs and thereby the signal produced is too late to be used as an indicator for the treatment of sleep apnea. There is often no displaced air volume in sleep apnea due to obstruction.
One measure that is effective in obstructive sleep apnea is tracheostomy. However, this surgical intervention carries considerable morbidity and is aesthetically unacceptable to many patients. Other surgical procedures include pulling the tongue as forward as possible and surgically cutting and removing sections of the tongue and other structures which can close off the upper airway passage.
There is a need for a method to treat air obstruction disorders that removes portions of the tongue without major surgical intervention.
SUMMARY OF THE INVENTIONAccordingly, an object of the invention is to provide a method for creating cell necrosis.
Another object of the invention is to provide a method for creating cell necrosis regions in the tongue.
Still another object of the invention is to provide a method for reducing the size of the tongue.
Yet another object of the invention is to provide a method for the treatment of airway obstructions.
A further object of the invention is to provide a method for the treatment of sleep apnea.
Another object of the invention is to provide a method for creating cell necrosis regions in the tongue by introducing one or more energy delivery devices through an underside of the tongue and delivering energy to the interior of the tongue.
Still a further object of the invention is to provide a method for creating cell necrosis regions in the tongue by introducing one or more energy delivery devices through a chin skin through and into the interior of the tongue.
These and other objects of the invention are achieved in a method for creating cell necrosis in an interior of the tongue. A cell necrosis apparatus is provided that includes an energy delivery device configured to be coupled to an energy source. At least one energy delivery device is introduced through an undersurface of the tongue into the interior of the tongue. A sufficient amount of energy is delivered from the energy delivery device into the interior of the tongue to create a cell necrosis region in the interior of the tongue without permanently damaging a main branch of the hypoglossal nerve. The energy delivery device is then removed from the interior of the tongue.
In another embodiment, the energy delivery device is introduced through a chin skin surface and the undersurface of the tongue into the interior of the tongue.
BRIEF DESCRIPTION OF THE FIGURESFIG. 1 is a perspective view of an apparatus for treating air way obstructions of the present invention.
FIG. 2 is a cross-sectional view of the apparatus of FIG. 1 as it is positioned around a patient's jaw and behind the tongue.
FIG. 3 is a perspective view of an electrode deployment device suitable for use with the present invention.
FIG. 4 is a cross-sectional view of the electrode deployment device of FIG. 3 taken along the lines 4--4.
FIG. 5 is a perspective view of the apparatus of FIG. 1 including a handle.
FIG. 6 is a block diagram of the electronics of the temperature feedback device of the present invention.
FIG. 7 illustrates a block diagram illustrating the incorporation of a microprocessor.
FIG. 8 is a schematic diagram illustrating the relationship of the device of FIG. 1 with ultrasound, optical, energy source and solution sources.
DETAILED DESCRIPTIONThe present invention provides a method for reducing a volume of a tongue includes providing an ablation apparatus with an energy delivery device configured to be coupled to an energy source. The energy delivery device is positioned in an interior of the tongue. A sufficient amount of energy is delivered from the energy delivery device in the interior of the tongue to ablate a section of the tongue without damaging the main branches of the hypoglossal nerve. The energy delivery device is thereafter removed from the interior of the tongue.
In another embodiment, the energy delivery device is advanced through a chin skin surface and the undersurface of the tongue into the interior of the tongue.
Referring to FIG. 1, an apparatus for treating air way obstructions 10, is shown. Apparatus 10 is used to treat a variety of different obstructions in the body where passage of gas is restricted. One embodiment is the treatment of sleep apnea using apparatus 10 to ablate selected portions of the tongue by the use of RF microwave, and the like. Apparatus 10 can be used to ablate targeted masses including but not limited to the tongue, tonsils, turbinates, soft palate tissues, hard tissue and mucosal tissue.
Apparatus 10 can include a first arm 12 with a distal end 12' and a proximal end 12". A second arm 14 has a distal end 14' and a proximal end 14". First arm 12 and second arm 14 are connected by a coupling device 16. Coupling device can be a ratchet hinge 16 and the like. Hinge 16 provides a coupling force that pulls arm 12 and arm 14 together. Also included are a retractor/guide rail 10', spreadable slide block 10", local cooling ports 10'" and ultrasound imager or transducers 10"".
In another embodiment, apparatus 10 has only one arm which can be a handpiece or an introducer.
As shown in FIG. 2, arm 12 is adapted to be inserted into a patient's throat. Distal end 12' is then positioned in an adjacent relationship to a back surface of the tongue and in certain embodiments presses up against the tongue. Distal end 12' is positioned under the jaw. When so positioned, hinge 16 causes distal end 12' to be in intimate contact with the back of the tongue. Similarly, hinge 16 pushes distal end 14' against the bottom portion of the jaw. Apparatus 10 is then positioned to provide a controlled creation of cell necrosis regions in selected interior areas of the tongue without damaging a main branch of a hypoglossal nerve.
Referring again to FIG. 1, one or more RF electrodes 18 extend from proximal end 12" to distal end 12'.RF electrodes 18 extend through the body of first arm 12, through lumens formed in the body of first arm 12, or through a single arm which can be a handpiece or an introducer. As shown in FIGS. 3 and 4, RF electrodes 18 are advanced and retracted in and out of the tongue with an optional electrode deployment device 20. Suitable deployment devices 20 include but are not limited to mechanical pull cables 20', a spreader/roller 20", which advance and retract RF electrodes 18 in and out of the targeted ablation mass, such as the tongue.
Second arm 14 can also include one or more RF electrodes 18. These electrodes are advanced and retracted in and out of the bottom portion of the tongue. The same or a suitable deployment device 20 is coupled to this set of RF electrodes 18. RF electrodes 18 can be operated in bipolar or monopolar modes.
Referring to FIG. 5, each RF electrode 18 has a insulation sleeve 21 slideably positioned around its exterior. A suitable insulation material is polyimide. Insulation sleeves 21 are advanced and retracted along an exterior longitudinal surface of RF electrodes 18 and define an ablation surface which delivers RF energy to the tongue or other desired tissue site. Coupled with insulation sleeves 21 is one or more insulation sleeve advancement and retraction actuators 22.
First and second arm proximal ends 12" and 14" are coupled to a handle 24. A visualization apparatus 26, with or without eyepiece, can be coupled to handle 24.
As shown in FIG. 1, one or more sensors 28 are positioned in an interior or exterior of RF electrodes 18, or at a surface of first and second arms 12 and 14. Sensors 28 permit accurate measurement of temperature or impedance at a tissue site in order to determine, (i) the extent of ablation, (ii) the amount of ablation, (iii) whether or not further ablation is needed, (iv) the boundary or periphery of the ablated mass and (v) prevents nontargeted tissue from being destroyed or ablated.
Sensors 28 are of conventional design, including but not limited to thermistors thermocouple, resistive wires, and the like. Suitable thermal sensors 28 include a T type thermocouple with copper constantene, J type, E type, K type, thermistors, fiber optics, resistive wires, thermocouple IR detectors, and the like. It will be appreciated that sensors 28 need not be thermal sensors.
Sensors 28 measure temperature and/or impedance to permit monitoring and a desired level of ablation to be achieved without destroying too much tissue. This reduces damage to tissue surrounding the targeted mass to be ablated. By monitoring the temperature at various points within the interior of the selected mass, a determination can be made when ablation is complete. If at any time sensor 28 determines that a desired ablation temperature is exceeded, then an appropriate feedback signal is received at an energy source which then regulates the amount of energy delivered to RF electrodes 18.
Thus the geometry of the ablated mass is selectable and controllable. Any number of different ablation geometries can be achieved.
Referring again to FIG. 1, an air or oxygen lumen 30 is included in first arm 12 and extends from proximal end 12" to distal end 12'. Lumen 30 provides air flow to the lungs during the ablation procedure. Any number of different lumens can also be incorporated into first or second arm 12 or 14. For example, in certain embodiments it may be desirable to include an anesthesia lumen 32 that is coupled to an anesthesia source. Further, a multiplexer can be coupled to RF electrodes 18 to provide ablation at different sites and at different time periods for varying lengths of time.
Resources, which can be hardware, software, or a combination of both, are connected with sensors 28, electrodes 18 and energy source 34 to provide an output for delivering and maintaining a selected energy at electrodes 18. Further, the resources provides an output that maintains a selected energy at primary and secondary antennas for a selected length of time.
The following discussion pertains particularly to the use of an RF energy source 34 and RF electrodes 18. It will be appreciated that devices similar to those associated with RF electrode 18 can be utilized with laser optical fibers, microwave devices and the like.
Referring now to FIG. 6, a sensor feed apparatus is coupled to sensors 28 maintains a tissue adjacent to RF electrodes 18 at a desired temperature for a selected period of time. Each RF electrode 18 is connected to resources which generate an independent output for each RF electrode 18. Further, the resources provides an output that maintains a selected energy at RF electrodes for a selected length of time.
Current delivered through RF electrodes 18 is measured by current sensor 36. Voltage is measured by voltage sensor 38. Impedance and power are then calculated at power and impedance calculation device 40. These values can then be displayed at user interface and display 42. Signals representative of power and impedance values are received by controller 44.
A control signal is generated by controller 44 that is proportional to the difference between an actual measured value, and a desired value. The control signal is used by power circuits 46 to adjust the power output in an appropriate amount in order to maintain the desired power delivered at the respective RF electrodes.
In a similar manner, temperatures detected at sensors 28 provide feedback for maintaining a selected power. The actual temperatures are measured at temperature measurement device 48, and the temperatures are displayed at user interface and display 42. A control signal is generated by controller 44 that is proportional to the difference between an actual measured temperature, and a desired temperature. The control signal is used by power circuits 46 to adjust the power output in an appropriate amount in order to maintain the desired temperature delivered at the respective sensor. A multiplexer can be included to measure current, voltage and temperature, at the numerous sensors 28, and energy can be delivered to RF electrodes in Monopolar or bipolar fashion.
Controller 44 can be a digital or analog controller, or a computer with software. When controller 44 is a computer it can include a CPU coupled through a system bus. On this system can be a keyboard, a disk drive, or other non-volatile memory systems, a display, and other peripherals, as are known in the art. Also coupled to the bus are a program memory and a data memory.
User interface and display 42 includes operator controls and a display. Controller 44 can be coupled to imaging systems, including but not limited to ultrasound, CT scanners, X-ray, MRI, mammographic X-ray and the like. Further, direct visualization and tactile imaging can be utilized.
The output of current sensor 36 and voltage sensor 38 is used by controller 44 to maintain a selected power level at RF electrodes 18. The amount of RF energy delivered controls the amount of power. A profile of power delivered can be incorporated in controller 44, and a preset amount of energy to be delivered can also be profiled.
Circuitry, software and feedback to controller 44 result in process control, and the maintenance of the selected power that is independent of changes in voltage or current, and are used to change, (i) the selected power, (ii) the duty cycle (on-off and wattage), (iii) bipolar or monopolar energy delivery and (iv) infusion medium delivery, including flow rate and pressure. These process variables are controlled and varied, while maintaining the desired delivery of power independent of changes in voltage or current, based on temperatures monitored at sensors 28.
Referring now to FIG. 7, current sensor 36 and voltage sensor 38 are connected to the input of an analog amplifier 50. Analog amplifier 50 can be a conventional differential amplifier circuit for use with sensors 28. The output of analog amplifier 50 is sequentially connected by an analog multiplexer 52 to the input of A/D converter 54. The output of analog amplifier 50 is a voltage which represents the respective sensed temperatures. Digitized amplifier output voltages are supplied by A/D converter 54 to a microprocessor 56. Microprocessor 56 may be a type 68HCII available from Motorola. However, it will be appreciated that any suitable microprocessor or general purpose digital or analog computer can be used to calculate impedance or temperature.
Microprocessor 56 sequentially receives and stores digital representations of impedance and temperature. Each digital value received by microprocessor 56 corresponds to different temperatures and impedances.
Calculated power and impedance values can be indicated on user interface and display 42. Alternatively, or in addition to the numerical indication of power or impedance, calculated impedance and power values can be compared by microprocessor 56 with power and impedance limits. When the values exceed predetermined power or impedance values, a warning can be given on user interface and display 42, and additionally, the delivery of RF energy can be reduced, modified or interrupted. A control signal from microprocessor 56 can modify the power level supplied by power source 34.
Referring now to FIG. 8, visualization apparatus 26 can include a light source, associated illumination and imaging fibers 60, which can be in the form of a flexible endoscope, and associated switch 62 that operates the rotation and viewing of viewing optics 64. Visualization apparatus 26 can also include an output going to a VCR, camera, and the like, and a feedback output to energy source 34 and controller 44. Energy source 34 can incorporate a controller, as well as both temperature and impedance monitoring devices. Infusion medium source 66 can include a pump/pressure flow control device 68, as is well known to those skilled in the art. An ultrasound source 70 is coupled to one or more ultrasound transducers 10"" that are positioned in or on the tongue. An output is associated with ultrasound source 70 and energy source 34.
Each ultrasound transducer 10"" can include a piezoelectric crystal mounted on a backing material. The piezoelectric crystal is connected by electrical leads to ultrasound power source 72. Each ultrasound transducer 10"" transmits ultrasound energy into adjacent tissue, such as the tongue. Ultrasound transducers 10"" can be in the form of an imaging probe such as Model 21362, manufactured and sold by Hewlett Packard Company.
The foregoing description of a preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. It is intended that the scope of the invention be defined by the following claims and their equivalents.
Claims
1. A method for creating cell necrosis in an interior of the tongue, comprising:
- providing a cell necrosis apparatus including an energy delivery device configured to be coupled to an energy source;
- introducing at least one energy delivery device through an undersurface of the tongue into the interior of the tongue;
- delivering a sufficient amount of energy from the energy delivery device into the interior of the tongue to create a cell necrosis region in the interior of the tongue without permanently damaging a main branch of the hypoglossal nerve; and
- removing the energy delivery device from the interior of the tongue.
2. The method of claim 1, wherein the energy source is an RF source.
3. The method of claim 1, wherein the energy source is a microwave source.
4. The method of claim 1, wherein two or more energy delivery devices are introduced through different tongue undersurface sites of the tongue to create different cell necrosis regions in the interior of the tongue.
5. The method of claim 1, wherein the energy delivery device is coupled to a handpiece.
6. The method of claim 5, wherein at least a portion of the handpiece is positioned adjacent to the undersurface of the tongue.
7. The method of claim 1, wherein the cell necrosis apparatus further comprises:
- an introducer including a lumen, wherein the energy delivery device is deployable from the introducer lumen into the interior of the tongue.
8. The method of claim 7, wherein the introducer further includes:
- a temperature control device.
9. The method of claim 8, wherein the temperature control device comprises a cooling channel in an interior of the introducer, the cooling channel receiving a cooling medium and circulating the cooling medium through the interior of the introducer.
10. The method of claim 9, further comprising:
- cooling the undersurface of the tongue while energy is delivered from the energy delivery device to the interior of the tongue.
11. The method of claim 1, further comprising:
- providing an imaging apparatus.
12. The method of claim 11, wherein the imaging apparatus is an ultrasound device.
13. The method of claim 11, further comprising:
- imaging the tongue prior to creating the cell necrosis region.
14. The method of claim 11, further comprising:
- imaging the tongue after creating the cell necrosis region.
| 1798902 | March 1931 | Raney |
| 3901241 | August 1975 | Allen, Jr. |
| 4011872 | March 15, 1977 | Komiya |
| 4196724 | April 8, 1980 | Wirt et al. |
| 4411266 | October 25, 1983 | Cosman |
| 4423812 | January 3, 1984 | Sato |
| 4532924 | August 6, 1985 | Auth et al. |
| 4565200 | January 21, 1986 | Cosman |
| 4901737 | February 20, 1990 | Toone |
| 4906203 | March 6, 1990 | Margrave et al. |
| 4907589 | March 13, 1990 | Cosman |
| 4943290 | July 24, 1990 | Rexroth et al. |
| 4947842 | August 14, 1990 | Marchosky et al. |
| 4966597 | October 30, 1990 | Cosman |
| 4976711 | December 11, 1990 | Parins et al. |
| 5046512 | September 10, 1991 | Murchie |
| 5057107 | October 15, 1991 | Parins et al. |
| 5078717 | January 7, 1992 | Parins et al. |
| 5083565 | January 28, 1992 | Parins |
| 5094233 | March 10, 1992 | Brennan |
| 5100423 | March 31, 1992 | Fearnot |
| 5122137 | June 16, 1992 | Lennox |
| 5125928 | June 30, 1992 | Parins et al. |
| 5190541 | March 2, 1993 | Abele et al. |
| 5197963 | March 30, 1993 | Parins |
| 5197964 | March 30, 1993 | Parins |
| 5215103 | June 1, 1993 | Desai |
| 5256138 | October 26, 1993 | Burek et al. |
| 5257451 | November 2, 1993 | Edwards et al. |
| 5275162 | January 4, 1994 | Edwards et al. |
| 5277201 | January 11, 1994 | Stern |
| 5281216 | January 25, 1994 | Klicek |
| 5281217 | January 25, 1994 | Edwards et al. |
| 5281218 | January 25, 1994 | Imran |
| 5290286 | March 1, 1994 | Parins |
| 5293869 | March 15, 1994 | Edwards et al. |
| 5309910 | May 10, 1994 | Edwards et al. |
| 5313943 | May 24, 1994 | Houser et al. |
| 5314466 | May 24, 1994 | Stern et al. |
| 5316020 | May 31, 1994 | Truffer |
| 5328467 | July 12, 1994 | Edwards et al. |
| 5334196 | August 2, 1994 | Scott et al. |
| 5348554 | September 20, 1994 | Imran et al. |
| 5363861 | November 15, 1994 | Edwards et al. |
| 5365926 | November 22, 1994 | Desai |
| 5365945 | November 22, 1994 | Halstrom |
| 5366490 | November 22, 1994 | Edwards et al. |
| 5368557 | November 29, 1994 | Nita et al. |
| 5368592 | November 29, 1994 | Stern et al. |
| 5370675 | December 6, 1994 | Edwards et al. |
| 5370678 | December 6, 1994 | Edwards et al. |
| 5383876 | January 24, 1995 | Nardella |
| 5383917 | January 24, 1995 | Desai |
| 5385544 | January 31, 1995 | Edwards et al. |
| 5397339 | March 14, 1995 | Desai |
| 5398683 | March 21, 1995 | Edwards et al. |
| 5401272 | March 28, 1995 | Perkins |
| 5403311 | April 4, 1995 | Abele et al. |
| 5409453 | April 25, 1995 | Lundquist et al. |
| 5421819 | June 6, 1995 | Edwards et al. |
| 5423808 | June 13, 1995 | Edwards et al. |
| 5423811 | June 13, 1995 | Imran et al. |
| 5423812 | June 13, 1995 | Ellman et al. |
| 5433739 | July 18, 1995 | Sluijter et al. |
| 5435805 | July 25, 1995 | Edwards et al. |
| 5441499 | August 15, 1995 | Fritzsch |
| 5456662 | October 10, 1995 | Edwards et al. |
| 5456682 | October 10, 1995 | Edwards et al. |
| 5458596 | October 17, 1995 | Lax et al. |
| 5458597 | October 17, 1995 | Edwards et al. |
| 5470308 | November 28, 1995 | Edwards et al. |
| 5471982 | December 5, 1995 | Edwards et al. |
| 5472441 | December 5, 1995 | Edwards et al. |
| 5484400 | January 16, 1996 | Edwards et al. |
| 5486161 | January 23, 1996 | Lax et al. |
| 5505728 | April 9, 1996 | Ellman et al. |
| 5505730 | April 9, 1996 | Edwards |
| 5507743 | April 16, 1996 | Edwards et al. |
| 5509419 | April 23, 1996 | Edwards et al. |
| 5514130 | May 7, 1996 | Baker |
| 5514131 | May 7, 1996 | Edwards et al. |
| 5520684 | May 28, 1996 | Imran |
| 5531676 | July 2, 1996 | Edwards et al. |
| 5531677 | July 2, 1996 | Lundquist et al. |
| 5536240 | July 16, 1996 | Edwards et al. |
| 5536267 | July 16, 1996 | Edwards et al. |
| 5540655 | July 30, 1996 | Edwards et al. |
| 5542915 | August 6, 1996 | Edwards et al. |
| 5542916 | August 6, 1996 | Hirsch et al. |
| 5545161 | August 13, 1996 | Imran |
| 5545171 | August 13, 1996 | Sharkey et al. |
| 5545193 | August 13, 1996 | Fleischman et al. |
| 5545434 | August 13, 1996 | Huarng |
| 5549108 | August 27, 1996 | Edwards et al. |
| 5549644 | August 27, 1996 | Lundquist et al. |
| 5554110 | September 10, 1996 | Edwards et al. |
| 5556377 | September 17, 1996 | Rosen et al. |
| 5558672 | September 24, 1996 | Edwards et al. |
| 5558673 | September 24, 1996 | Edwards et al. |
| 5599345 | February 4, 1997 | Edwards et al. |
| 5609151 | March 11, 1997 | Mulier et al. |
| 5624439 | April 29, 1997 | Edwards et al. |
| 0 139 607 A1 | May 1985 | EPX |
| 0 608 609 A2 | August 1994 | EPX |
| 43 03 882 | February 1995 | DEX |
| 38 38 840 | August 1997 | DEX |
| 92/10142 | June 1992 | WOX |
| 93/08755 | May 1993 | WOX |
| 94/10925 | May 1994 | WOX |
| 94/26178 | November 1994 | WOX |
| 95/18575 | July 1995 | WOX |
| 95/19142 | July 1995 | WOX |
| 95/25472 | September 1995 | WOX |
| 96/29946 | October 1996 | WOX |
- Kaneko, et al., Physiological Laryngeal Pacemaker, May 1985, Trans Am Soc Artif Intern Organs, vol. XXXI, pp. 293-296. Mugica, et al., Direct Diaphragm Stimulation, Jan., 1987; Pace, vol. 10, pp. 252-256. Mugica, et al., Neurostimulation: An Overview, Chapter 21, Preliminary Test of a Muscular Diaphragm Pacing System on Human Patients, 1985, pp. 263-279. Nochomovitz, et al., Electrical Activation of the Diaphragm, Jun. 1988, Clinics in Chest Medicine, vol. 9, No. 2, pp. 349-358. Prior, et al., Treatment of Menorrhagia by Radiofrequency Heating, 1991, Int. J. Hyperthermia, vol. 7, pp. 213-220. Rice, et al., Endoscopic Paranasal Sinus Surgery, Chapters 5, Functional Endoscopic Paranasal Sinus Surgery, The Technique of Messerklinger, Raven Press, 1988, pp. 75-104. Rice, et al., Endoscopic Paranasal Sinus Surgery, Chapters 6, Total Endoscopic Sphenoethmoidectomy, The Technique of Wigand, Raven Press, 1988, pp. 105-125.
Type: Grant
Filed: Apr 3, 1998
Date of Patent: Nov 28, 2000
Assignee: Somnus Medical Technologies, Inc. (Sunnyvale, CA)
Inventor: Stuart D. Edwards (Portola Valley, CA)
Primary Examiner: V. Milliw
Assistant Examiner: Kelly O'Hara
Law Firm: Wilson Sonsini Goodrich & Rosati
Application Number: 9/55,133
International Classification: A61B 1900;
